Mesa Laboratories (MLAB)
(Delayed Data from NSDQ)
$116.04 USD
-1.07 (-0.91%)
Updated May 10, 2024 04:00 PM ET
After-Market: $115.79 -0.25 (-0.22%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth C Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
MLAB 116.04 -1.07(-0.91%)
Will MLAB be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for MLAB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MLAB
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
Best Value Stocks to Buy for April 8th
MLAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Mesa Labs (MLAB) Lags Q3 Earnings and Revenue Estimates
Reasons to Add Integer Holdings (ITGR) to Your Portfolio Now
Rapid Micro Biosystems, Inc. (RPID) Reports Q3 Loss, Tops Revenue Estimates
Other News for MLAB
Evercore ISI removes several healthcare names from 'Tactical Outperform' list
25 GDP-sensitive Small-Cap stocks with low refinancing risk - BofA
MESA LABS ANNOUNCES AMENDMENT TO CREDIT FACILITY AND REPURCHASE OF SENIOR CONVERTIBLE NOTES
Mesa Labs announces amendment to credit facility, repurchase of notes
Mesa Laboratories Enhances Financial Structure and Reduces Debt